Table 2. Univariate analysis of the gene expression and immune cells infiltration-related biomarkers.
| OS | PFS | |||
|---|---|---|---|---|
| Variable | Median survival (months) | p-value | Median survival (months) | p-value |
| Gene expression markers (N=122) | ||||
| Tumoral CD4 High vs. low |
81.2 vs. 42.9 | 0.018 | 37.8 vs. 23 | 0.042 |
| Tumoral CD8 High vs. low |
81.2 vs. 37.2 | <0.001 | 81.2 vs. 19.4 | 0.001 |
| Stromal CD8 High vs. low |
74.3 vs. 46.4 | 0.032 | 29.1 vs. 25.6 | 0.237 |
| Tumoral FOXP3 High vs. low |
NR vs. 37.2 | 0.005 | 35.3 vs. 22.1 | 0.020 |
| Tumoral LAG3 High vs. low |
69 vs. 36.2 | 0.023 | 30.1 vs. 22.1 | 0.107 |
| Tumoral TGBF1 High vs. low |
74.3 vs. 46.6 | 0.032 | 31.5 vs. 22.1 | 0.174 |
| Ratio FOXP3stroma/ CD4tumor High vs. low |
46.6 vs. 81.2 | 0.012 | 19.4 vs. 37.8 | 0.013 |
| Ratio FOXP3stroma/ CD8tumor High vs. low |
46.4 vs. 74.3 | 0.025 | 23 vs. 37.8 | 0.042 |
| Immune cells markers (N=84) | ||||
| Tumoral CD8+ cells High vs .Low | 73.9 vs. 40.4 | 0.021 | 56.8 vs. 23 | 0.026 |
| Stromal FOXP3+ cells High vs. low |
37.2 vs. 68 | 0.029 | 17.4 vs. 46.6 | 0.101 |
| FOXP3+ stroma/ CD4+ tumor High vs. low |
17.4 vs. 66.9 | 0.024 | 32.5 vs. 15.3 | 0.086 |
| FOXP3+ stroma/ CD8+ tumor High vs. low |
17.4 vs. 68.8 | 0.011 | 15.3 vs. 35.9 | 0.035 |
NR, not-reached; OS, overall survival; PFS, progression free survival. The p-value was calculated using the log-rank test.